News

Guest User 6/3/22 Guest User 6/3/22

Zymeworks Presents

Zymeworks Presents Results of the Completed Dose Escalation Portion of the Ongoing Phase 1 Study of ZW25 at the San Antonio Breast Cancer Symposium

Guest User 6/3/22 Guest User 6/3/22

Zymeworks Announces License Agreement with Johnson & Johnson Innovation to Develop and Commercialize Next Generation Bispecific Antibody Therapeutics

Guest User 6/3/22 Guest User 6/3/22

PreciThera, Inc. Completes $36M Series A Financing

Guest User 6/3/22 Guest User 6/3/22

Zymeworks Announces Pricing of Initial Public Offering

Guest User 6/3/22 Guest User 6/3/22

Immunovaccine Announces Positive Interim Clinical Data from Ovarian Cancer Study of DPX

Guest User 6/3/22 Guest User 6/3/22

SutroVax Announces Closing of $64M via Series B Financing

Guest User 6/3/22 Guest User 6/3/22

CellAegis Devices Announces US$9.5 Million Financing to Support Clinical and Regulatory Advancement of its autoRIC® Device